Palantir's DoD contracts, strong Q1 2025 growth, and competitive edge in AI-driven platforms make it a standout growth ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Kestra Medical Technologies, Ltd. sees sales growth but struggles with losses and slowing revenue. Click for risks tied to ...

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

Rivian's initial promise has faded amid ongoing losses, weak BEV demand, and significant capital burn. Click here to read an ...

May jobs printed at 139,000, exceeding expectations. Job creation seems to undermine earlier prognostications that President ...

Booking Holdings' growth is slowing, with choppy bookings trends and decelerating revenue. Click here to find out why I ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

Healthcare Realty Trust is dealing with post-merger challenges and volatility. Read my analysis of HR and why its HOLD rating ...